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the hospital perspective of costs from hospital admission through 
discharge. A decision analysis model was developed to incorporate 
costs and outcomes associated with prophylaxis treatment success 
or failure, which resulted in the need for empirical therapy and 
developing fungal infection. Clinical outcomes for no prophylaxis 
were derived from a review of published literature. Clinical out- 
comes for prophylaxis with micafungin were based on the results 
of the clinical study. Published literanlre was used to assess hospi- 
tal costs associated with I ISCT patients treated with prophylaxis 
treatment, reated with empirical anti-fimgal treatment, and with 
a probable or proven infection. The cost per course of micafungin 
was varied as part of a sensitivity analysis. In addition, sensitivity 
analyses were performed to evaluate the impact of all assmnptions 
on hospital results. RESULTS. Hospital costs were $136,000 per 
episode for proven/probably infection, $91,000 for empirical ther- 
apy, and $64,000 for no empirical therapy. The model indicated 
that mean total hospital costs were $81,500 for patients with no 
prophylaxis compared to $69,200 for micafimgin prophylaxis. The 
results of the model were sensitive to assumptions about he need 
for empirical therapy and likelihood of developing a fungal infec- 
tion. CONCLUSION. Micafnngin prophylaxis n HSCT reduces 
hospital costs compared to no prophylaxis. Micafungin treatment 
reduces hospital costs due to: (1) decreased use of empirical anti- 
fungal therapy and (2) lower rates of probable and proven fungal 
infection. 
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LIPOSOMAL AMPHOTERICIN B (AMB) PROPHYLAXIS IS SAFE AND 
EFFECTIVE IN PREVENTING INVASIVE FUNGAL.INFECTIONS (IFI) IN 
RELATED AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTA- 
TION (ASCT) 
OstlJdewo, I4 Coolle3', E.; Bessmertny, 0.; DiNatale, J.; Gm'vin, J.; 
Gzi1"o, M.S. ChildveMr Hospital ofNew FoT"k PresbyteHmT, Cohtmbia 
University, New Yo'rk, NY. 
IFI especially with Aspergilhis (ASG) (10-20%) is a leading 
cause of infectious mortality in ASCT recipients (Wingard, 
BBMT 5:55, 1999). Fhiconazolc (F) prophylaxis has been the 
standard approach to prevent IFI (7% failures) (Goodman et aI, 
NEJM 326:845, 1992; Slavin et al, JID 171:1545, 1995). F is, how- 
ever, ineffective against ASG IFI compared to Amphotericin B
(AmphoB) or AmB. Walsh et al (NJEM 340:764, 1999) reported 
that AraB compared to AmphoB in pts developing fever/neutrope- 
nia (45 % BMT pts) was associated with significantly fewer break- 
through IFI (3.2 vs. 7.8%, p<0.009), less infusion related reac- 
tions, and less nephrotoxicity (both p<0.001). We initiated a pilot 
study to determine the safety and efficacy of prophylactic AraB in 
ASCT recipients. 26 pts (29 ASCT) without previous history of 
IFI were given Arab (3 mg/kg/day) IV (day 0-100). Median age 8 
yrs (0.5-22), 8 F, 18 M. Dx: 5 ALL (3 CR2, 2 CR3), 4 HD (2 
CR2, 1 PR2, 1 PD), 2 AML (1 CR1, 1 Rel), 1 APL CR1, 2 NHL 
CR2, 3 CML, 1 Wihns' PD, 1 NBL PR, 1 Hurler's, 1 WAS, 1 
HLH, 1 SAA, 1 SS, 2 'Fhal. 3 pts had a second ASCT for graft 
failure, tILA typing class A and B (serology) and class II DRBI 
(high resolution) were performed. Donors: 16 UCB: 4 5/6 class l, 
10 4/6 (6 double class I, 4 class I/II mismatch); 9 R-PBSC (8 6/6 
and l 5/6) and 3 6/6 R-BM. 15 ASCT were myeloablative, 14 sub- 
myeloablative. GVHD prophylaxis: tacrolimus/mycophenolate 
mofetil (MMF) n=28; cyclosporine/MMF/prednisone n=l. 
Results: 4/29 ASCT (13%) required premedication for fever and 
rigors. Median follow-up is 2 I2d (28-62 Id). 2 t% developed grade 
3 elevated creatinine while 35% had correctable _>grade 3 
hypokalemia 2 ° to multiple nephorotoxiris. No pt had AraB dis- 
continued for toxicity. Incidence of >grade 2 AGVtID and 
CGVHD was 48% and 7%, respectively. Most importantly, 
despite 48% AGVHD there was only one (3.5%) docmnented IFI 
(Candida parapsilosis) and no (0%) ASG IF1. Estinmted 1-yr OS is 
61.5% and no deaths 2 ° to IFI and no evidence of IFI on 3/3 
autopsies. These prelimina W results suggest prophylactic Arab is 
tolerable and effective in preventing IFI post ASCT, especially 
ASG IFI. Larger randomized studies are needed to determine 
overall safety and long-term efficacy of this approach compared to 
standard prophylaxis regimens to prevent ASG IH. 
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SAFETY OF OUTPATIENT HIGH DOSE ORAL BUSULFAN IN PATIENTS 
UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT) 
Emami, M., Comlnghmz, D.G.; Llo/land, H.K.; Mo'lTis, L.E. The Blood 
mzd Mar'row 7)vnsplant Gl"oap of Georgia at Not'thside Hospital, 
Atla,Tta, GA. 
One hundred and fifty-four consecutive patients received a mye- 
loablative oral busulfan (Bu) containing preparative r gimen prior to 
I ICT. Patients were screened fbr compliance and provided compre- 
hensive verbal and written education prior to chemotherapy initia- 
tion. After screening, seven patients were excluded due to medica- 
tion noncompliance (3), insurance requiring hospitalization (1), and 
hospitalization for a febrile episode (3). Following a test dose, busul- 
fan area under the concentration curve (AUC) was measured and 
dosage adjustments were made to target an AUC of 1200 ng 
mii1/mL. M1 patients received oral anticonvulsant prophylaxis con- 
sisting of phenytoin or gabapentin. Demographics included a medi- 
an age of 45 years (range 20-68 years) with 66 female and 81 male 
patients. Ninety-six patients underwent an autologous HCT versus 
51 allogeneic HCT for the following diagnoses: 58 Non-Hodgkin's 
lymphoma, 12 Hodgkin's disease, 36 multiple myeloma, 23 acute 
lmtkemia, 12 chronic leukemia, and 6 other diagnoses. Preparative 
regimens consisted of 38 BuCy2, 106 BuCy2 and etoposide, and 3 
other Bu containing regimens. Primary endpoints included number 
of repeat doses secondary to emesis, number of patients hospitalized 
secondary to oral Bu intolerance, and incidence of seizures or veno- 
occlusive disease (VOD). Additional Bu dosing occurred in 26 
patients (17.7%) with a median of 1.5 repeated oses per patient. 
Five patients (3.4%) required hospitalization while receiving oral Bu. 
Of the 135 patients evaluated for Bu adverse events; only 2 (1.5%) 
experienced a generalized seiznre, with one patient having a history 
of a seizure disorder. Based on the Baltimore criteria for VOD diag- 
nosis, only 4 patients (3%) were determined to have VOD, with 2 
patients having lymphoma involvement of the liver prior to HCT. 
VOD resolved in 3 patients and was a contributing cause of death in 
1 patient. Following determination f the Bu test dose AUC, 82 
patients required less than and 13 required more than the standard 
high dose Bu, 16 mg/kg based on ideal body weight. In conclusion, 
with appropriate selection and a comprehensive educational process, 
high dose oral Bu can be safely administered on an outpatient basis 
to patients undergoing HCT. Most patients required a ownward 
adjustment oftheir Bu following determination f the AUC. 
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AMBISONE® I MG/KG/DAY AS EMPIRIC ANTIFUNGAL THERAPY IN 
PATIENTS WITH PROLONGED NEUTROPENIA AND FEVER 
DeUoe, M.; He3&lg, K.; Bromz, E.R.; Essell, jr.; Sig'm, mTd, D.; TieJTze~, 
C.; Keller, S. BMT Pvogram, Jewi.rh Hospital, Cinci~n~ati, OH. 
Empiric use of amphotericin the setting of patients with pro- 
longed neutropenia and fever is frequently complicated by renal 
toxicity. The lipid-based forms of amphotericin are associated 
with much less renal toxicity but are significantly more expensive 
than standard amphotericin B. Since June 1999 we have used 
Ambisome@ at a dose of lmg/kg/day as empiric antifungal thera- 
py. We have reviewed this experience in patients who are neu- 
tropenic (ANC < 500/mL), febrile (T> 380 C for >72 hours) and 
on broad-spectrum antibiotics. Forty-three patients met these cri- 
teria. Of these 14 received allogeneic transplant (9 unrelated, 5
related donors) for CML (5), AML (3), ALL (1), MDS (2), MM 
(1); 10 autologous transplant for NHL (6), MM (3), testis (1); 18 
leukemic induction and 1 high dose chemotx without ransplant. 
All had recdved fluconazole prophylaxis. Twenty-seven of forty- 
three (63%) defervesced within 72 hours of starting Ambisome@ 
lmg/kg/day. Only 1/43 (2.3%) developed a positive fungal blood 
cultur, e while receiving this dose of Ambisolne@ and that was 
Candida kruseii related to an infected central venous catheter. 
One patient had Fusarium detected on bronchoscopy and expired 
despite dose escalation to 5 mg/kg/d. The results of this retro- 
spective review compare f:avorably with trials using Ambisome® 3 
mg/kg/d in this setting. At our institution a 14 day course of 
kanbisome® hng/kg/d in a 70 kg patient costs $1976.24 coin- 
pared to $4940.60 for the same patient reated a 3mg/kg/d. YVhilc 
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